Lamotrigine treatment in childhood drug resistant epilepsy

J Child Neurol. 1998 Apr;13(4):163-7. doi: 10.1177/088307389801300403.

Abstract

The clinical response to lamotrigine has been evaluated in a group of 63 drug resistant epileptic children in an open add-on trial. A negative response was observed in 30 subjects. In 11 patients, after an initial improvement lasting a mean period of 8 months, seizures recurred with the same frequency present before the beginning of the treatment. Twenty-two patients responded to lamotrigine treatment. Period of observation in the responsive group ranged from 1 year to 3 years. Response was complete in 16 patients and in the other 6 a 50% to 90% decrease of seizures was obtained. A complete normalization of the electroencephalogram (EEG) was registered in 10 cases after a mean period of 5 months of therapy. Side effects were mild and limited to 12 patients. Improvement was obtained in social and academic performance. Writing ability improved in one case. Lamotrigine can be considered a useful drug in the therapeutic armamentarium for childhood drug resistant epilepsy.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Anticonvulsants / therapeutic use*
  • Child
  • Child, Preschool
  • Cognition / drug effects
  • Electroencephalography / drug effects
  • Epilepsy / drug therapy*
  • Epilepsy / physiopathology
  • Female
  • Humans
  • Infant
  • Lamotrigine
  • Male
  • Seizures
  • Social Behavior
  • Treatment Outcome
  • Triazines / therapeutic use*

Substances

  • Anticonvulsants
  • Triazines
  • Lamotrigine